Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004479|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
Determine the efficacy of midodrine, a selective alpha 1 adrenergic agonist, in preventing neurally mediated syncope.
|Condition or disease||Intervention/treatment||Phase|
|Syncope||Drug: midodrine||Not Applicable|
PROTOCOL OUTLINE: This is a randomized, double-blind, crossover, placebo-controlled study.
On day one, patients receive either midodrine or placebo. On day three, patients receive the opposite drug.
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||March 1999|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004479
|United States, New York|
|Mount Sinai School of Medicine|
|New York, New York, United States, 10029|
|Study Chair:||Horacio Kaufmann||Icahn School of Medicine at Mount Sinai|